The effect of nebivolol on atherogenesis in apoE - Knockout mice

Journal of Physiology and Pharmacology

Volumn 60, Issue 4, 2009, Pages 163-165

  Kus, K ^a   Gajda, M ^a   Pyka Fosciak, G ^a   Toton Zuranska, J ^a   Pawlowska, M ^a   Suski, M ^a   Niepsuj, A ^a   Nowak, B ^a   Wolkow, P ^b   Olszanecki, R ^a   Jawien, Jacek ^a   Korbut, R ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b NONE

Author keywords

ApoE Knockout mice; Atherosclerosis; Nebivolol

Indexed keywords

APOLIPOPROTEIN E; LIPID; NEBIVOLOL;

ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZOPYRANS; CHOLESTEROL; ETHANOLAMINES; FEMALE; MICE; MICE, KNOCKOUT; RECEPTORS, ADRENERGIC, BETA-1; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; VASODILATOR AGENTS;

EID: 75749113321     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
2. Weiss R. Nebivolol: a novel beta-blocker with nitric oxideinduced vasodilatation. Vasc Health Risk Manag 2006; 2:303-308.
3. Thakur NK, Hayashi T, Sumi D, et al. Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis. J Cardiovasc Pharmacol 2002; 39: 298-309.
4. de Nigris F, Mancini FP, Balestrieri ML, et al. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. Nitric Oxide 2008; 19: 57-63.
5. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-517.
6. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-4475.
7. Plump AS, Smith JD, Hayek T, Aalto-Setela K, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E - deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
8. Huebbe P, Jofre-Monseny L, Boesch-Saadatmandi C, Minihane AM, Rimbach G. Effect of apoE genotype and vitamin E on biomarkers of oxidative stress in cultured neuronal cells and the brain of targeted replacement mice. J Physiol Pharmacol 2007; 58: 683-698.
9. Savla U. At the heart of atherosclerosis. Nat Med 2002; 8:1209.
10. Jawien J, Gajda M, Rudling M, et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006; 36: 141-146.
11. Jawien J, Gajda M, Wolkow P, et al. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2008; 59: 633-639.
12. Jawien J, Gajda M, Olszanecki R, Korbut R. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol 2007; 58: 583-588.
13. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000; 102: 677-684.
14. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-1205.
15. Mollnau H, Schulz E, Daiber A, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23: 615-621.
16. Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006; 48: 677-684.
17. Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after baloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007; 19: 129-136.
18. Baumhakel M, Schlimmer N, Buyukafsar K, Arikan O, Bohm M. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice. J Pharmacol Exp Ther 2008; 325: 818-823.
19. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.
20. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104: 511-514.